Efficacy of Ketorolac tromethamine and Etoricoxib with and without Benzydamine Hydrochloride Mouthwash in alleviating post operative pain and promoting wound healing after Periodontal Flap Surgery-A Randomized Controlled trial - NIL

Start Date10 Dec 2024

Sponsor / Collaborator-

CTRI/2024/08/072901 / Not yet recruitingPhase 3IIT

Comparing the effectiveness of novel VG111(Sepil) with Benzydamine on radiation induced oral mucositis and QoL in head and neck cancer subjects: A Randomized Controlled Trial. - NIL

Start Date23 Aug 2024

Sponsor / Collaborator

Indian Council of Medical Research

CTRI/2024/03/063581 / CompletedPhase 2/3IIT

Comparison of clinical efficacy of Benzydamine Hydrochloride oral rinses versus normal saline rinses to satisfy analgesic requirements post orthodontic premolar extraction - A comparative split mouth study. - NIL

Start Date14 Mar 2024

Sponsor / Collaborator-

100 Clinical Results associated with Benzydamine Hydrochloride

100 Translational Medicine associated with Benzydamine Hydrochloride

100 Patents (Medical) associated with Benzydamine Hydrochloride

561

Literatures (Medical) associated with Benzydamine Hydrochloride

01 Sep 2024·Journal of Medical Imaging and Radiation Sciences

Patient perceptions of advanced practice radiation therapists prescribing medication in radiation therapy

Article

Author: Doerwald-Munoz, Lilian ; Farrell, Thomas ; Uppal, Jasleen Kaur ; Smoke, Marcia

INTRODUCTION:

The purpose of this study was to determine patient perceptions of an advanced practice radiation therapist (APRT) prescribing medication for radiation therapy treatment-related side effects. By comprehending patient perceptions, it is important to implement change in order to improve patients' quality of life.

METHODS:

A literature review was conducted on advanced practice (AP) roles in Canada and world-wide; the roles searched were: APRT, nurse practitioner and pharmacist. The search focused on evidence demonstrating improvements made to patient care due to the implementation of these roles. Based on this review and input from a team of experts a qualitative semi-structured interview survey was designed, and pilot tested. The survey consisted of five open-ended questions, which were designed to determine patient satisfaction of an APRT prescribing medication over the course of their radiation therapy treatments. Patients undergoing head and neck radiation therapy treatments at a large, academic cancer centre were invited to participate. Six patients who had a head and neck APRT involved in their treatment were interviewed. A comprehensive thematic analysis was then conducted using the transcripts created from these interviews, which was followed by two independent blinded analyses to ensure validity of the results.

DISCUSSION:

The thematic analysis produced four salient themes which were: side effect management, care provided by the APRT in comparison to other healthcare workers, patients' access to care, and overall patient satisfaction. Common medications for head and neck radiation therapy treatment related side effects were discussed and these were: Magic Mouthwash, Xylocaine, Nystatin, Benadryl, Advil, Tylenol, Dexamethasone, Tantum, Biotene, Mucaine, Flamazine, Hydrocortisone, Ondansetron, Senokot, and narcotics.

CONCLUSION:

This study was valuable to understand patient experiences and provide evidence to change processes in order to improve quality of patient centered care. The study revealed that although patients were happy with the process of prescribing medication, they all agreed that having an advanced practice radiation therapist prescribe would improve care. Patient responses further demonstrated the need for future research in regards to side effect management as a whole by APRTs as well as how role clarification can impact patient perceptions of APRTs.

02 Jul 2024·Xenobiotica; the fate of foreign compounds in biological systems

Exploring precision-cut liver slices for comparative xenobiotic metabolism profiling in swine and cattle

Article

Author: Viviani, Paula ; Ichinose, Paula ; Miró, María Victoria ; Lifschitz, Adrián ; Herrera, Juan Manuel ; Virkel, Guillermo

In vitro systems are useful tools for unravelling species differences in xenobiotic metabolism.The current work aimed to validate the technique of precision-cut liver slices (PCLS) for comparative studies on xenobiotic metabolism in swine and cattle.PCLS from swine (n = 3) and cattle (n = 3) were produced using a Brendel-Vitron^TM Tissue Slicer and cultured for 6 h. Tissue viability was preserved throughout the whole culture period.Metabolic viability was evaluated using the anthelmintics albendazole (ABZ) and fenbendazole (FBZ) as model drugs, as well as other substrates of hepatic monooxygenases: benzydamine (BZ) N-oxygenase (FMO-dependent), and the O-dealkylations of 7-ethoxyresorufin (EROD, CYP1A1-dependent) and 7-methoxyresorufin (MROD, CYP1A2-dependent).ABZ S-oxygenation resulted 6-fold (cattle) and 13.6-fold (swine) higher (p = 0.001) compared to FBZ S-oxygenation.Similar BZ N-oxygenation and EROD activities were observed in PCLS cultures from both species. MROD was 2.5-fold higher (p = 0.033) in swine than in cattle. Similarly, ABZ S-oxygenation was 1.7-fold higher (p = 0.0002) in swine than in cattle. Conversely, a 82% higher (p = 0.0003) rate of FBZ S-oxygenation was evidenced in PCLS cultures from cattle compared to those from swine.Overall, this work shows that PCLS cultures are useful to obtain relevant information on species differences in xenobiotic metabolism.

01 Jul 2024·European journal of dentistry

In Vitro Model to Evaluate the Development of Discolorations on Human Enamel Caused by Treatment with Mouth Rinses and Black Tea Considering Brushing

Article

Author: Sarembe, Sandra ; Michler, Nicole ; Ufer, Carolin ; Kiesow, Andreas

Abstract:

Objectives The study aimed to develop and test an in vitro model to investigate the staining potential of mouth rinses on human enamel, considering alternating intake of black tea and tooth brushing, thus mimicking the situation in the oral cavity more realistically. Materials and Methods Eight mouth rinses with six different active ingredients (benzydamine hydrochloride [BNZ], polyhexamethylene biguanide hydrochloride [PHMB], chlorhexidine digluconate [CHX], hexetidine gluconate [HEX], octenidine dihydrochloride [OCT] and octenidine dihydrochloride + 2-phenoxyethanol [OCTP]) and concentrations were tested. Sets of six halved human molar crowns were initially pretreated by soaking in artificial saliva (30 min). Afterward, the cyclic treatment was started by soaking in artificial saliva (2 min), staining with black tea (1 min), brushing with toothpaste (5 s), and soaking in the mouth rinse (30 s). Samples were rinsed with distilled water after each treatment step. The cyclic treatment was repeated 30 times, mimicking the consumer behavior after 15 days. Photographic images were taken after 0, 10, 20, and 30 cycles. Color measurements were conducted after each staining and brushing step using a VITA-Easyshade spectrophotometer to determine the difference in lightness ∆L and the total color difference ∆E. Statistical Analysis Analysis of variance and post-hoc Tukey test (α = 0.05) were applied. Results The new testing model with included brushing sequences allowed to assess the staining behavior on human teeth and provided a clear differentiation between the different investigated products. In detail, up to cycle 10, ΔE values increased for all mouth rinses with each additional cycle number. However, while ΔE values continued to increase for 0.15% BNZ, 0.1% PHMB, and 0.2% CHX between treatment cycle 10 and 30, ΔE values only slightly increased after treatment with 0.08% OCTP, 0.1% OCTP, 0.1% OCT, and 0.1% HEX. After 20 and 30 cycles, significantly less staining was found for 0.08% OCTP, 0.1% OCT, 0.1% HEX as compared to 0.2% CHX, 0.15% BNZ, and 0.1% PHMB (p < 0.05). ΔE-values were significantly lower after treatment with 0.1% OCTP as compared to 0.2% CHX1 and 0.2% CHX2 (p < 0.05). Conclusion The proposed new methodology was found to be appropriate for assessing the staining progression of mouth rinses over a simulated application period of 15 days. The model allows differentiation of products with different active ingredients and concentrations.

News (Medical) associated with Benzydamine Hydrochloride

06 Apr 2023

·firstwordpharma.com

Sources say iNova in talks to buy Mundipharma's OTC unit: report

iNova Pharmaceuticals is said to be in advanced talks to acquire Mundipharma's over-the-counter (OTC) business for a potential value of $700 million, Bloomberg reported Thursday citing people familiar with the matter. Negotiations are ongoing and there is no guarantee that an agreement will be reached, the people said.A report last year indicated that the Sackler family's attempt to sell Mundipharma's Chinese assets for more than $1 billion had stalled after bids failed to meet expectations. The plan to offload Mundipharma China came as the Sacklers offered over $4 billion in a settlement for Purdue Pharma, another drug company they own, to resolve ongoing opioid lawsuits in the US.Mundipharma focuses on pain management, infectious diseases and other serious illnesses. Its consumer health business includes the antiseptic Betadine. Meanwhile, iNova Pharma specialises in distributing a range of pharmacy products and prescription medicines, including brands like Difflam, Duro-Tuss, Demazin and Dequadin.Last year, TPG acquired a majority stake in iNova Pharma, while Pacific Equity Partners re-invested as a minority stakeholder.

AcquisitionPatent Infringement

09 Feb 2023

·www.businesswire.com

UnitedHealthcare Provides Commercial Coverage for FoundationOne®CDx and FoundationOne®Liquid CDx in Multiple Companion Diagnostic Indications

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Foundation Medicine, Inc. , a pioneer in molecular profiling for cancer, announced today that UnitedHealthcare commercial plans will cover FoundationOne®CDx as a companion diagnostic in all solid tumors for patients with unresectable or metastatic cancer being considered for treatment with an immune checkpoint inhibitor and meeting coverage criteria. Additionally, FoundationOne®Liquid CDx will be covered as a companion diagnostic for patients with advanced breast cancer, metastatic non-small cell lung cancer (NSCLC), recurrent ovarian cancer and metastatic castrate-resistant prostate cancer (mCRPC) meeting coverage criteria. Coverage is effective April 1, 2023. FoundationOne CDx, a tissue-based comprehensive genomic profiling (CGP) test, and FoundationOne Liquid CDx, a CGP liquid biopsy test, are used to identify patients who may benefit from treatment with specific FDA-approved targeted therapies. “We believe patients and their physicians deserve the highest quality genomic testing to make informed decisions about personalized treatment,” said Foundation Medicine Chief Executive Officer Brian Alexander, M.D., M.P.H. “UnitedHealthcare’s coverage decision will improve patient access to molecular profiling and enable better outcomes for patients.” UnitedHealthcare’s planned coverage of FoundationOne CDx and FoundationOne Liquid CDx is in addition to coverage that Foundation Medicine already has for these tests from other national and regional commercial providers, as well as by Medicare and Medicare Advantage plans. About Foundation Medicine: Your Essential Partner in Cancer Care Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn . About FoundationOne CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com . About FoundationOne Liquid CDx FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com . Source: Foundation Medicine

Clinical Study

30 Nov 2022

·www.biospace.com

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne

--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable to that from two U.S. FDA approved acne drugs - WINLEVI® and TWYNEO® --In the previous Phase II clinical trial of non-alcoholic steatohepatitis (NASH) patients with 12-week treatment of 50 mg ASC40 once daily, 61% patients showed ≥ 30% relative decrease of liver fat HANGZHOU and SHAOXING, China, Nov. 30, 2022 /PRNewswire/ -- Ascletis, Inc. (HKEX: 1672, "Ascletis") announces today the completion of 180 patient enrollment for the Phase II clinical trial of ASC40 (denifanstat) for treatment of moderate to severe acne. The study is currently still blind. To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023. Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable to that from two recently approved acne drugs by U.S. Food and Drug Administration - WINLEVI® and TWYNEO® [1,2], in terms of percentage change from baseline in total lesion counts and percentage change from baseline in inflammatory and non-inflammatory lesion counts. To date, the preliminary data also indicated that ASC40 or placebo treatment in acne patients is safe and well tolerated, and majority of treatment-related adverse events are grade 1. In the previous Phase II clinical trial of non-alcoholic steatohepatitis (NASH) patients with 12-week treatment of 50 mg ASC40 once daily, 61% patients showed ≥ 30% relative decrease of liver fat[3]. The current Phase II clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40 for the treatment of patients with moderate to severe acne. 180 enrolled patients have been randomized into three active treatment arms or one placebo control arm at the ratio of 1:1:1:1 to receive ASC40 (25 mg, 50 mg or 75 mg) or matching placebo orally once daily for 12 weeks. The primary outcomes include percentage change of total lesion count at week 12 compared with baseline and/or ratio of subjects, whose Investigator's Global Assessment (IGA) grades are decreased by ≥2 grades at week 12 compared with baseline. ASC40 is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). Human sebum production requires de novo lipogenesis, which is increased in acne and can be suppressed by the FASN inhibitor ASC40. Acne is the eighth most prevalent disease in the world and affects more than 640 million people globally[4]. The onset of acne often coincides with pubertal hormonal changes, and the condition affects approximately 85% of adolescents and young adults aged 12 to 25 years[5]. However, acne can also persist into or develop during adulthood. Current first-line treatments for acne include topical creams such as topical retinoids, androgen receptor inhibitor, oral isotretinoin, and antibiotics, but still have various limitations. "Excess sebum production plays a significant role in the pathogenesis of acne and suppression of sebum production reduces acne incidence and severity. As a first-in-class drug with a novel mechanism, FASN inhibitor ASC40 has demonstrated exciting preliminary efficacy in Phase I clinical trial. We will continue to accelerate the Phase II study to provide more options for patients with moderate to severe acne." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of ASC40 Phase II trial for moderate to severe acne. "Moderate to severe acne poses lasting impact on patients and remains a huge unmet medical needs globally. I'm very happy that FASN inhibitor ASC40 for acne has completed the patient enrollment for Phase II study, which marks a new milestone as Ascletis is exploring the market of consumer healthcare." said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 22 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). For more information, please visit . Company Codes: HongKong:1672

Phase 2Clinical ResultPhase 1

100 Deals associated with Benzydamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01410	Benzydamine Hydrochloride	A01AD02 G02CC03 M01AX07	DB09084

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	CN	Shaanxi Xinfenghe Pharmaceutical Co., Ltd.	01 Jan 1983
Musculoskeletal Pain	CN	Shaanxi Xinfenghe Pharmaceutical Co., Ltd.	01 Jan 1983
Soft Tissue Infections	CN	Shaanxi Xinfenghe Pharmaceutical Co., Ltd.	01 Jan 1983

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucositis	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	13 Jan 2003
Nasopharyngeal Neoplasms	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	13 Jan 2003
Radiation Injuries	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	13 Jan 2003
Stomatitis	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	13 Jan 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04373421 (CTgov)	Phase 4	Postoperative Complications	90	Chlorhexidine Gluconate+benzydamine hydrochloride (Chlorhexidine Gluconate Plus Benzydamine Hydrochloride)	eheocsgpum(xtqlplfhcm) = vdfrrpaxsm sabyrsjcod (xyzdajmxpo, agrmovgesp - jpulkeujub) View more	-	01 Nov 2021
				St. John's wort oil (St. John's Wort Oil)	eheocsgpum(xtqlplfhcm) = mxihdrtbfc sabyrsjcod (xyzdajmxpo, kaqxpvaslb - htmkoypewf) View more
NCT04167592 (Pubmed \| BMC Anesthesiol)	Not Applicable	-	72	Benzydamine hydrochloride gargle	uanzbvxjjm(qnxhgvxvhc) = zbjggmuzpo zndqknuvex (ortegixpdr )	-	23 May 2020
				Water gargle	uanzbvxjjm(qnxhgvxvhc) = fbuysqkxou zndqknuvex (ortegixpdr )
NCT03074968 (Pubmed)	Phase 4	Pharyngitis	142	Benzydamine hydrochloride spray	ifbykhjtjl(pnziwkkrau) = xyatjqheby jfwfnbkbdz (dvnznvlnrx )	-	04 Apr 2020
				benzydamine hydrochloride (Control)	ifbykhjtjl(pnziwkkrau) = ujccqkbmzx jfwfnbkbdz (dvnznvlnrx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis